US › Healthcare

Champions Oncology Inc (CSBR)

US · Healthcare · Biotechnology

$5.08+2.63%

Last close · 2026-09-17

Latest quarter · ended 2026-07-31

Revenue

$15.2M

Revenue YoY

+8.8%

Net profit

$-426,000

EPS

$-0.03

EPS estimate

$-0.01

Net margin

-2.8%

EPS came in at -0.03 against a street estimate of -0.01 — a miss of 200.0%.

Key statistics

Market cap

$70.8M

Forward P/E

22.9

P/B

17.70

Book value

$0.28

EPS (TTM)

$-0.08

52-week high

$8.74

52-week low

$4.83

50-day MA

$5.45

200-day MA

$6.07

Beta

0.40

Analyst view

Analysts rate Champions Oncology Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $12.00.

Shareholding

Insiders

26.33%

Institutions

48.71%

Largest institutional holders

Fund	Stake
Battery Management Corp	17.43%
NEA Management Company, LLC	12.33%
Tocqueville Asset Management L.P.	2.30%
Vanguard Capital Management, LLC	2.16%
Morgan Stanley - Brokerage Accounts	1.74%
Renaissance Technologies Corp	1.05%
BlackRock Inc	0.89%
Mink Brook Asset Management LLC	0.80%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Champions Oncology Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.